NCT07065968View on ClinicalTrials.gov

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

September 10, 2027

Study Completion Date

December 30, 2027

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

Teriflunomide

Teriflunomide 14 mg orally once daily for 24 weeks.

DRUG

Dexamethasone

Dexamethasone 40 mg orally once daily for four consecutive days.

Trial Locations (3)

100034

RECRUITING

Peking University First Hospital, Beijing

100044

RECRUITING

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

100191

RECRUITING

Peking University Third Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Peking University Health Science Center

OTHER

collaborator

Cisen Pharmaceutical CO., LTD.

INDUSTRY

lead

Peking University People's Hospital

OTHER

NCT07065968 - The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) | Biotech Hunter | Biotech Hunter